Advanced Inhalation Therapies (AIT Ltd.), an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). NOxCureCF is a specialized formulation of inhaled Nitric Oxide (NO) delivered using AIT's patented drug delivery system.
David Greenberg, M.D., AIT's Chief Medical Officer and a professor of pediatrics and infectious diseases at Soroka Medical Center in Beersheva, Israel, said: "This study, in combination with the continuation of our Phase II trial of the use of NO for treatment of infants with RSV/bronchiolitis, will allow us to substantiate and enhance the use of inhaled NO in the treatment of respiratory disease and distress."
Prof. Asher Tal, head of the Pediatrics Department at Soroka University Medical Center, adds: "The NOxCureCF treatment may serve as a major improvement in the quality of life for CF patients, and may significally contribute to their life expectancy." The study takes place at Soroka's CF Clinic, which is led by Dr. Micha Aviram.